FDA Clears IND Application for Abpro's Lead Multispecific Antibody Cancer Candidate
I'm PortAI, I can summarize articles.
Abpro Holdings Inc. and Celltrion, Inc. have received FDA clearance for their IND application for the multispecific antibody cancer candidate ABP-102 / CT-P72. This approval allows them to start a Phase 1 clinical trial targeting HER2-positive solid tumors, expected to begin in the first half of 2026. The trial will evaluate the therapy's safety, tolerability, pharmacokinetics, and preliminary efficacy as part of a global collaboration between the companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments